(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 August 2009 (27.08.2009)

PCT

(10) International Publication Number
WO 2009/105269 A1

(51) **International Patent Classification**:
C07K 16/22 (2006.01) *C07K 19/00* (2006.01)
A61K 39/395 (2006.01) *C07K 14/00* (2006.01)
A61P 35/00 (2006.01)

(21) **International Application Number**:
PCT/US2009/001122

(22) **International Filing Date**:
20 February 2009 (20.02.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/066,632 20 February 2008 (20.02.2008) US
61/061,943 16 June 2008 (16.06.2008) US
61/139,361 19 December 2008 (19.12.2008) US

(71) **Applicant** *(for all designated States except US)*: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320 (US).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **BOONE, Thomas, C.** [US/US]; 2715 Kelly Knoll Lane, Newbury Park, California 91320 (US). **OLINER, Jonathan, D.** [US/US]; 959 Golden Crest Avenue, Newbury Park, California 91320 (US).

(74) **Agent**: **PENN, Michael, G.**; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2009/105269 A1

(54) **Title**: ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 AND USE THEREOF

(57) **Abstract**: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.